Normal vision. Courtesy NIH National Eye InstituteThe same view with tunnel vision from retinitis pigmentosa
Find information on thousands of medical conditions and prescription drugs.

Retinitis pigmentosa

Retinitis pigmentosa, or RP, is a genetic eye condition. Generally, night blindness precedes tunnel vision by years or even decades. Many people with RP do not become legally blind until their 40s or 50s and retain some sight all their life. more...

Home
Diseases
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
Gastroesophageal reflux...
Rabies
Radiophobia
Rasmussen's encephalitis
Raynaud's phenomenon
Reactive arthritis
Reactive hypoglycemia
Reflex sympathetic...
Regional enteritis
Reiter's Syndrome
Renal agenesis
Renal artery stenosis
Renal calculi
Renal cell carcinoma
Renal cell carcinoma
Renal cell carcinoma
Renal failure
Renal osteodystrophy
Renal tubular acidosis
Repetitive strain injury
Respiratory acidosis
Restless legs syndrome
Retinitis pigmentosa
Retinoblastoma
Retinoschisis
Retrolental fibroplasia
Retroperitoneal fibrosis
Rett syndrome
Reye's syndrome
Rh disease
Rhabdomyolysis
Rhabdomyosarcoma
Rheumatic fever
Rheumatism
Rheumatoid arthritis
Rickets
Rift Valley fever
Ringworm
Rocky Mountain spotted fever
Romano-Ward syndrome
Roseola infantum
Rubella
Rubeola
Rubinstein-Taybi syndrome
Rumination disorder
S
T
U
V
W
X
Y
Z
Medicines

Others go completely blind from RP, in some cases as early as childhood. Progression of RP is different in each case.

RP is a group of inherited disorders in which abnormalities of the photoreceptors (rods and cones) or the retinal pigment epithelium (RPE) of the retina lead to progressive visual loss. Affected individuals first experience defective dark adaptation or nyctalopia (night blindness), followed by constriction of the peripheral visual field and, eventually, loss of central vision late in the course of the disease.

Signs

Mottling of the retinal pigment epithelium with bone-spicule pigmentation is typically pathognomonic for retinis pigmentosa. Other ocular features include waxy pallor of the optic nerve head, attenuated retinal vessels, cellophane maculopathy, cystic macular edema, and posterior subcapsular cataract.

Diagnosis

The diagnosis of RP relies upon documentation of progressive loss in photoreceptor function by electroretinography (ERG) and visual field testing. The mode of inheritance of RP is determined by family history. At least 35 different genes or loci are known to cause nonsyndromic RP. DNA testing is available on a clinical basis for RLBP1 (autosomal recessive, Bothnia type RP), RP1 (autosomal dominant, RP1), RHO (autosomal dominant, RP4), RDS (autosomal dominant, RP7), PRPF8 (autosomal dominant, RP13), PRPF3 (autosomal dominant, RP18), CRB1 (autosomal recessive, RP12), ABCA4 (autosomal recessive, RP19), and RPE65 (autosomal recessive, RP20). For all other genes, molecular genetic testing is available on a research basis only.

RP can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. X-linked RP can be either recessive, affecting primarily only males, or dominant, affecting both males and females, although females are always more mildly affected. Some digenic and mitochondrial forms have also been described. Genetic counseling depends on an accurate diagnosis, determination of the mode of inheritance in each family, and results of molecular genetic testing. RP combined with progressive deafness is called Usher syndrome.

Treatment

There is currently no medical treatment for retinitis pigmentosa, although scientists continue to investigate possible treatments. Future treatments may involve retinal transplants, artificial retinal implants , gene therapy, stem cells, nutritional supplements, and/or drug therapies.

Sources

Jones BW, CB Watt, JM Frederick, W Baehr, CK Chen, EM Levine, AH Milam, MM LaVail, RE Marc 2003 Retinal remodeling triggered by photoreceptor degenerations. J Comp Neurol 464: 1-16.

Marc RE, BW Jones 2003 Retinal remodeling in inherited photoreceptor degenerations. Molecular Neurobiology 28: 139-148.

Read more at Wikipedia.org


[List your site here Free!]


Postmortem study of ataxia with retinitis pigmentosa by mutation of the alpha-tocopherol transfer protein gene
From Alternative Medicine Review, 10/1/00

Postmortem study of ataxia with retinitis pigmentosa by mutation of the alpha-tocopherol transfer protein gene. Yokota T, Uchihara T, Kumagai J, et al. J Neurol Neurosurg Psychiatry 2000;68:521-525.

A new syndrome of ataxia and retinitis pigmentosa with vitamin E deficiency caused by the missense mutation of alpha-tocopherol transfer protein (alpha-TTP) gene was recently proposed. After studying the first postmortem case with this mutation pathologically and biochemically, whether the symptoms can be treated by supplementation of vitamin E or not is discussed. The major pathological findings were retinal atrophy; severe dying back-type degeneration of the posterior column; and massive accumulation of lipofuscin in neurons including dorsal root ganglion (DRG) cells, which were almost identical to those in vitamin E deficient animals and patients with fat malabsorption. Also, mild loss of Purkinje cells was noted. Because robust expression of alpha-TTP was detected in the cerebellum as well as in the liver and the tissue concentration of vitamin E in the cerebellum was still low even after oral supplementation, the mild Purkinje cell loss might be related to the mutant alpha-TTP in the cerebellum. By contrast, in the DRG, thought to be mainly responsible for ataxia, no expression of alpha-TTP was detected, and the tissue concentration of vitamin E increased to normal after supplementation. It is therefore considered that oral supplementation of vitamin E should effectively counteract the progression of ataxia.

COPYRIGHT 2000 Thorne Research Inc.
COPYRIGHT 2000 Gale Group

Return to Retinitis pigmentosa
Home Contact Resources Exchange Links ebay